The overall goal of the Endometrial Cancer SPORE at MD Anderson Cancer Center is to conduct highly innovative translational research for the prevention and treatment of endometrial cancer. To ensure the success of the SPORE, the Administrative Core will provide scientific oversight, as well as effective management and administration of all activities relating to each Project, Core, and Developmental Research/Career Enhancement Program in the SPORE. The Administrative Core will actively work to communicate and disseminate information within our internal SPORE investigators as well as facilitate information sharing and collaborations with other SPOREs and external constituencies. The Core will provide a structure to integrate diverse scientific disciplines into a unified multidisciplinary approach for achieving excellence in translational endometrial cancer research. Importantly, the Administrative Core will monitor timelines and ensure both basic science and clinical trial aims are met for all SPORE projects. The objectives of the Core are to 1) oversee all SPORE activities, including Projects and Cores; 2) provide administrative support for the DRP and CEP; 3) convene all meetings of the SPORE Executive Committee (all Program Co-leaders and Core Co-directors), Internal/External Advisory Committees, and Advocate Advisory Committee; 4) schedule all scientific meetings; 5) coordinate data quality control and quality assurance issues in collaboration with the Biostatistics and Bioinformatics Core, Pathology Core, and Biomarkers Core; 6) monitor and oversee all fiscal and budgetary issues; 7) interface closely with the other oversight committees related to endometrial cancer research at our institution, including the Gynecological Oncology Tumor Bank Oversight Committee; 8) maintain communication and coordinate research among investigators, as well as with other translational researchers, gynecologic cancer SPOREs, the Gynecologic Oncology Group, and SPOREs from other disease sites by distributing materials, electronic communications, and progress reports; 8) communicate with the NCI Project Officer and other staff to prepare all required reports and publications; 9) notify the NCI Project Officer promptly of important developments that affect the management of the SPORE either positively or negatively; 11) assure compliance with all general, governmental, and NCI regulations and requirements; and 12) establish and implement policies for recruitment of women and minorities. Dr. Karen Lu, Co-Director of the Administrative Core and Co-Principal Investigator for the overall SPORE, will direct these activities with the assistance of the Co-Director of the Administrative Core and Co-Principal Investigator for the overall SPORE, Dr. Russell Broaddus, as well as the SPORE Administrator, Mr. Heetae Kim.

Public Health Relevance

Administrative Core NARRATIVE The Administrative Core interfaces with the NCI and SPORE investigators to provide scientific, administrative, and financial oversight for all Projects and Cores and the Developmental Research and Career Enhancement Programs of the Endometrial Cancer SPORE. The Administrative Core also helps to provide vision for the overall function of the SPORE and development of new SPORE-related research, both clinical and laboratory- based.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098258-13
Application #
9552042
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
13
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yates, Melinda S; Coletta, Adriana M; Zhang, Qian et al. (2018) Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila) 11:477-490
Yan, F; Thall, P F; Lu, K H et al. (2018) Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol 29:694-699
Gao, Chao; Wang, Yingmei; Broaddus, Russell et al. (2018) Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget 9:5492-5508
Pan, Haitao; Liu, Suyu; Miao, Danmin et al. (2018) Sample size determination for mediation analysis of longitudinal data. BMC Med Res Methodol 18:32
Suidan, Rudy S; Sun, Charlotte C; Cantor, Scott B et al. (2018) Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol 132:52-58
Chu, Yiyi; Yuan, Ying (2018) A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin Trials 15:149-158
Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta et al. (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923
Crumley, Suzanne; Kurnit, Katherine; Hudgens, Courtney et al. (2018) Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol :
Mitamura, T; Pradeep, S; McGuire, M et al. (2018) Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37:722-731
Aslan, Ozlem; Cremona, Mattia; Morgan, Clare et al. (2018) Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. BMC Cancer 18:168

Showing the most recent 10 out of 578 publications